T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/5035828_CN35828_0